cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant

Affiliations

• ¹ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA. dlouis@mgh.harvard.edu.
• ² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
• ³ Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
• ⁴ Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany.
• ⁵ Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
• ⁶ Departments of Pathology and Neurological Surgery, University of Virginia, Charlottesville, VA, 22908, USA.
• ⁷ Departments of Neurology, Radiation Oncology and Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
• ⁸ Charbonneau Cancer Institute, University of Calgary, Calgary, AB, T2N4Z6, Canada.
• ⁹ The Brain Tumor Center at Erasmus MC Cancer Center, Rotterdam, The Netherlands.
• ¹⁰ Neurology Clinic and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
• ¹¹ Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
• ¹² German Cancer Consortium (DKTK) Core Center Heidelberg, Heidelberg, Germany.
• ¹³ Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
• ¹⁴ Department of Pathology, Princess Máxima Center for Pediatric Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.